Search results for "NOSOCOMIAL PNEUMONIA"

showing 3 items of 3 documents

Consensus document on controversial issues for the treatment of hospital-associated pneumonia

2010

Background: Hospital-associated pneumonia (HAP) remains an important cause of morbidity and mortality despite advances in antimicrobial therapy. Many aspects of the treatment of HAP caused by multi-resistant Gram-positive microorganisms have been extensively studied, but controversial issues remain. Controversial issues: The aim of this GISIG (Gruppo Italiano di Studio sulle Infezioni Gravi) working group – a panel of multidisciplinary experts – was to define recommendations for some controversial issues using an evidence-based and analytical approach. The controversial issues were: (1) Is combination antibiotic therapy or monotherapy more effective in the treatment of HAP? (2) What role do…

Microbiology (medical)medicine.medical_specialtyMEDLINECochrane LibraryGram-Positive BacteriaNosocomial pneumonia Health care-associated pneumonia 16Methicillin-resistant staphylococcilaw.inventionHealth care-associated pneumoniaRandomized controlled triallawSettore MED/41 - ANESTESIOLOGIAPneumonia BacterialHumansMedicineNOSOCOMIAL PNEUMONIAMethicillin-resistant staphylococciIntensive care medicineGram-Positive Bacterial InfectionsRandomized Controlled Trials as TopicCross InfectionEvidence-Based Medicinebusiness.industryBacterial pneumoniaRetrospective cohort studyGeneral MedicineEvidence-based medicinemedicine.diseaseAnti-Bacterial AgentsQuality of evidencePneumoniaTreatment OutcomeInfectious DiseasesDrug Therapy CombinationbusinessInternational Journal of Infectious Diseases
researchProduct

Drug resistance patterns of bacteria isolated from patients with nosocomial pneumonia at Tehran hospitals during 2009-2011

2013

Introduction: Nosocomial pneumonia remains an important cause of mortality and morbidity worldwide. Surveillance programs play an important role in the identification of common etiologic agents and local patterns of antimicrobial resistance. Methodology: In this study we determined the frequency and antimicrobial susceptibility of pathogens isolated from patients with nosocomial pneumonia during 2009 to 2011. Results: A total of 642 bacteria were isolated from 516 suspected samples. Acinetobacter baumannii (21.1%, n = 136), was the commonest isolated pathogen followed by Pseudomonas aeruginosa (17.4%, n = 112) , Staphylococcus aureus (15.8%, n = 102) and enterococci (8.4% n = 54). The most …

Acinetobacter baumanniiSettore MED/07 - Microbiologia E Microbiologia ClinicaPenicillanic AcidDrug resistanceIranmedicine.disease_causechemistry.chemical_compoundLevofloxacinDrug Resistance Multiple BacterialPrevalenceRespiratory Tract InfectionsPolymyxin BCross InfectionbiologyCeftriaxoneGeneral MedicineHospitalsAcinetobacter baumanniiAnti-Bacterial AgentsInfectious DiseasesPiperacillin Tazobactam Drug CombinationPseudomonas aeruginosaCeftriaxonemedicine.drugMethicillin-Resistant Staphylococcus aureusStaphylococcus aureusMicrobial Sensitivity TestsMicrobiologyTazobactamMicrobiologyAntibiotic resistanceAcinetobacter baumanniiiVirologymedicinePneumonia BacterialHumansTehran hospitalsGram-Positive Bacterial InfectionsPiperacillindrug resistancebusiness.industryPseudomonas aeruginosanosocomial pneumoniaSputumbiochemical phenomena metabolism and nutritionbacterial infections and mycosesbiology.organism_classificationchemistrynosocomial pneumonia; drug resistance; Acinetobacter baumanniii; Pseudomonas aeruginosa; Tehran hospitalsLinezolidParasitologybusinessGram-Negative Bacterial Infections
researchProduct

Clinical Experience with Ceftazidime-Avibactam for the Treatment of Infections due to Multidrug-Resistant Gram-Negative Bacteria Other than Carbapene…

2020

Background: Experience in real clinical practice with ceftazidime-avibactam for the treatment of serious infections due to gram&minus

Nosocomial pneumonia0301 basic medicineMicrobiology (medical)medicine.medical_specialtymedicine.drug_classmedicine.medical_treatment030106 microbiologyAntibioticscarbapenem-sparing regimenBiologymedicine.disease_causeBiochemistryMicrobiologyArticleCarbapenem-sparing regimen; Ceftazidime-avibactam; ESBL-producing Enterobacterales; Nosocomial pneumonia; Pseudomonas aeruginosa03 medical and health sciences0302 clinical medicineESBL-producing EnterobacteralesCarbapenem-sparing regimenInternal medicinemedicinePharmacology (medical)030212 general & internal medicineRenal replacement therapyGeneral Pharmacology Toxicology and PharmaceuticsRisk factorAdverse effectESBL-producing Enterobacterales; Pseudomonas aeruginosa; carbapenem-sparing regimen; ceftazidime-avibactam; nosocomial pneumoniaCeftazidime-avibactamPseudomonas aeruginosaceftazidime-avibactamnosocomial pneumonialcsh:RM1-950medicine.diseaseCeftazidime/avibactamPneumonialcsh:Therapeutics. PharmacologyInfectious DiseasesEndocrinologyBacteremiaPseudomonas aeruginosaESBL-producing Enterobacteralemedicine.drugAntibiotics
researchProduct